Balyasny Asset Management LLC Chimerix Inc Transaction History

Balyasny Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.1 - $1.54 $22,345 - $31,283	20,314 New	20,314 $24,000
Q3 2018 Nov 14, 2018	SELL	$3.58 - $4.9 $47,016 - $64,351	-13,133 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$4.43 - $5.14 $98,771 - $114,601	-22,296 Reduced 62.93%	13,133 $63,000
Q1 2018 May 15, 2018	BUY	$4.65 - $5.9 $83,700 - $106,200	18,000 Added 103.28%	35,429 $184,000
Q4 2017 Feb 14, 2018	BUY	$4.32 - $5.52 $75,293 - $96,208	17,429	17,429 $81,000

37M

52.7K

130K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $77.1M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.